iRadimed (NASDAQ:IRMD) Issues Q2 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its second quarter 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.440-0.480 for the period, compared to the consensus EPS estimate of 0.460. The company issued revenue guidance of $20.0 million-$21.0 million, compared to the consensus revenue estimate of $21.1 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

iRadimed Trading Up 4.4%

Shares of IRMD traded up $3.71 during mid-day trading on Friday, hitting $87.15. The company’s stock had a trading volume of 346,336 shares, compared to its average volume of 103,465. The firm has a 50-day simple moving average of $96.69 and a 200 day simple moving average of $93.87. The firm has a market capitalization of $1.11 billion, a P/E ratio of 49.80 and a beta of 0.91. iRadimed has a 1-year low of $50.31 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. The business had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, sell-side analysts predict that iRadimed will post 1.94 EPS for the current fiscal year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is currently 45.71%.

Wall Street Analysts Forecast Growth

IRMD has been the subject of several research reports. Freedom Capital raised iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $120.00.

Insider Transactions at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $101.38, for a total value of $506,900.00. Following the completion of the transaction, the chief executive officer directly owned 2,242,500 shares of the company’s stock, valued at $227,344,650. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 48,750 shares of company stock worth $4,708,950 over the last ninety days. Insiders own 36.80% of the company’s stock.

Key Headlines Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of iRadimed by 1.0% in the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after acquiring an additional 5,475 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of iRadimed by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after acquiring an additional 2,578 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of iRadimed by 37.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after acquiring an additional 55,426 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of iRadimed by 3.1% in the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after acquiring an additional 5,713 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.